Clinical Outcome of Rifabutin-based Treatment for Pulmonary Tuberculosis in Solid Organ Transplant Recipients.

ABSTRACT:

Backgrounds

Rifabutin is often used instead of rifampin to treat tuberculosis (TB) in solid organ transplant recipients (SOTRs) due to fewer drug interactions with immunosuppressants. However, data on its efficacy are limited.

Methods

A retrospective, case-control study was conducted at a tertiary care center in Korea. SOTRs aged ≥18 years with culture-positive pulmonary TB treated with isoniazid and rifabutin for >80% of the treatment duration were included. Those with rifampin-resistant TB or who discontinued immunosuppressants prior to TB diagnosis were excluded. Each SOTR was matched to three non-SOTR controls treated with rifampin-based regimens. The primary outcome was treatment completion without early relapse. Logistic regression with and without overlap weighting wa

SUBMITTER: Yang J 

PROVIDER: S-EPMC12502653 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature